To know the clinical outcomes of intravitreal bevacizumab with laser photocoagulation as primary treatment in the diabetic macular edema.


Patients who diagnosed with DME without vitreomacular traction and not underwent any other treatment were choosen to receive an intravitreal bevacizumab injection alone in 30 eyes and an intravitreal bevacizumab injection with laser photocoagulation in 31 eyes. We compared both groups. Best-corrected visual acuity (BCVA) and central macular thickness (CMT) at baseline and at six months after treatment were analyzed.


The number of bevacizumab injections was 1.70 ± 0.75 times in the bevacizumab alone group and 1.26 ± 0.44 times in the bevacizumab with laser photocoagulation group (p<0.05). In the bevacizumab alone group, CMT not significantly changed from 398.40±142.04 μm at baseline to 344.00±170.36 μm, while in the bevacizumab with laser photocoagulation group, CMT significantly decreased from 385.94±135.21 μm at baseline to 284.09±155.91 μm at the follow-up (p<0.05). The BCVA changed in the bevacizumab group from logMAR 0.85±0.70 to logMAR 0.81±0.72, and in the bevacizumab with laser photocoagulation group from logMAR 0.63±0.46 to logMAR 0.57±0.46. There was no significant difference with baseline VA in both groups.


The combined therapy of intravitreal bevacizumab injection and laser photocoagulation would reduce reinjection rate by suppression of recurrence. This combination therapy may be considered as primary treatment in diabetic macular edema, but longterm follow-up is needed.